Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,055,297 papers from all fields of science
Search
Sign In
Create Free Account
resminostat
An orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity. Resminostat binds to and inhibits HDACs…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Narrower (2)
4SC-201
RAS 2410
Broader (2)
Hydroxamic Acids
Sulfonamides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Acetylation of α-tubulin by a Histone Deacetylase Inhibitor, Resminostat, Leads Synergistic Antitumor Effect with Docetaxel in Non-Small Cell Lung Cancer Models
H. Konishi
2017
Corpus ID: 4152672
Background: There is a growing body of clinical evidence to demonstrate that inhibition of histone deacetylase is effective in…
Expand
2017
2017
Evaluation of a novel epi-virotherapeutic treatment strategy of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus
Tim Patrick Ellerhoff
2017
Corpus ID: 190897796
2015
2015
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma (HCC)
B. Ruf
,
S. Berchtold
,
+4 authors
U. Lauer
2015
Corpus ID: 80550540
2014
2014
Abstract 5534: A novel and oral histone deacetylase inhibitor, resminostat, effectively suppresses the growth of non-small cell lung cancer in a xenograft mouse model
Akimitsu Takagi
,
H. Konishi
,
+6 authors
T. Matsuzaki
2014
Corpus ID: 70838716
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Accumulating evidence reveals effectiveness of…
Expand
2012
2012
Combination Treatment of Sorafenib and Resminostat, a new HDAC Inhibitor, in Patients with Sorafenib-resistant Hepatocellular Carcinoma (HCC) – Results of the Dose-Escalation Phase
M. Bitzer
,
M. Horger
,
+11 authors
U. Lauer
2012
Corpus ID: 75175835
2011
2011
Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study.
M. Bitzer
,
M. Horger
,
+11 authors
U. Lauer
Journal of Clinical Oncology
2011
Corpus ID: 33092854
e13603 Background: Resminostat (4SC-201) is a novel oral pan-HDAC inhibitor in clinical development in a variety of cancer…
Expand
2010
2010
Resminostat in relapsed or refractory Hodgkin Lymphoma: Initial results of the SAPHIRE phase II trial with a novel oral histone deacetylase (HDAC) inhibitor
J. Walewski
,
E. Pasziewicz-Kozik
,
+8 authors
B. Hentsch
2010
Corpus ID: 74708467
The study has started in Jan 2010 and has completed accrual of the first 18 pts Background Resminostat in Relapsed or Refractory…
Expand
2010
2010
First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study.
M. Bitzer
,
M. Horger
,
+7 authors
U. Lauer
2010
Corpus ID: 70767407
e14661 Background: Resminostat (4SC-201) is a novel specific pan-HDAC inhibitor under clinical evaluation as mono or combination…
Expand
2010
2010
Central ECG analysis of resminostat, a new oral histone deacetylase inhibitor (HDACi), in clinical development as anticancer compound.
B. Hauns
,
A. Mais
,
R. Jankowsky
,
B. Hentsch
,
W. Haverkamp
2010
Corpus ID: 78277429
e13609 Background: Resminostat (4SC-201) is a new, specific, potent, pan-HDAC inhibitor with broad anti-tumor activity in…
Expand